- Noramco, an active pharmaceutical ingredients manufacturer, announces the launch of the Noramco Group.
- The group is a comprehensive North American-based supply chain solution, including subsidiaries Purisys, Noramco, and the newly acquired drug product CDMO, Halo Pharma.
- This strategic alignment aims to address critical issues in the pharmaceutical supply chain, primarily driven by lack of reliable foreign supply, limited domestic manufacturing capacity, and logistical bottlenecks.
Noramco, a global active pharmaceutical ingredients manufacturer, has announced the launch of the Noramco Group. The group includes subsidiaries Purisys, Noramco, and the newly acquired drug product CDMO, Halo Pharma.
Noramco, based in Wilmington, Delaware, supplies commercial APIs globally. Purisys, located in Athens, Georgia, offers specialized clinical API development and manufacturing services. Halo Pharma, with operations in Whippany, New Jersey, and Montreal, Quebec, is a contract development and manufacturing organisation (CDMO) that provides a wide range of manufacturing services.
The COVID-19 pandemic exposed critical vulnerabilities in our drug supply chain. Government responses, while well-intentioned, proved to be somewhat superficial, leaving the threat of future disruptions unaddressed. The formation of the Noramco Group is our proactive solution to some of these challenges. We are uniquely positioned to provide our customers with a complete, North American-based supply chain solution. By leveraging our advanced manufacturing capabilities, stringent quality control and compliance measures, and timely delivery, we aim to mitigate the risks associated with drug shortages and ensure a stable and reliable supply of vital APIs and drug products. We are committed to supporting patients by ensuring the supply of critical, lifesaving drugs,” says Lee Karras, CEO of the Noramco Group.
The new structure of the Noramco Group, which combines API and drug product CDMO services in North America, could open up more chances to get grants and contracts from the National Institutes of Health (NIH) and other government bodies. This important step puts the Noramco Group in a leading position in the U.S. pharmaceutical supply chain.
